Literature DB >> 15343371

Antiprion immunotherapy: to suppress or to stimulate?

Adriano Aguzzi1, Christina J Sigurdson.   

Abstract

Although human prion diseases are rare, they are invariably fatal, and treatments remain elusive. Hundreds of iatrogenic prion transmissions have occurred in the past two decades, and the bovine spongiform encephalopathy epidemic has raised concerns about prion transmission from cattle to humans. Research into therapeutics for prion disease is being pursued in several centres and prominently includes immunological strategies. Currently, the options that are being explored aim either to mobilize the innate and adaptive immune systems towards prion destruction or to suppress or dedifferentiate the lymphoreticular compartments that replicate prions. This article reviews the pathophysiology of prion diseases in mouse models and discusses their relevance to immunotherapeutic and immunoprophylactic antiprion strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343371     DOI: 10.1038/nri1437

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  21 in total

1.  Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.

Authors:  Claude Carnaud; Véronique Bachy
Journal:  Prion       Date:  2010-04-04       Impact factor: 3.931

2.  Processing of the bovine spongiform encephalopathy-specific prion protein by dendritic cells.

Authors:  Catherine Rybner-Barnier; Catherine Jacquemot; Céline Cuche; Grégory Doré; Laleh Majlessi; Marie-Madeleine Gabellec; Arnaud Moris; Olivier Schwartz; James Di Santo; Ana Cumano; Claude Leclerc; Françoise Lazarini
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Could immunomodulation be used to prevent prion diseases?

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

Review 4.  The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective.

Authors:  Heidi Martini-Stoica; Yin Xu; Andrea Ballabio; Hui Zheng
Journal:  Trends Neurosci       Date:  2016-03-09       Impact factor: 13.837

5.  De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis.

Authors:  Christina J Sigurdson; K Peter R Nilsson; Simone Hornemann; Mathias Heikenwalder; Giuseppe Manco; Petra Schwarz; David Ott; Thomas Rülicke; Pawel P Liberski; Christian Julius; Jeppe Falsig; Lothar Stitz; Kurt Wüthrich; Adriano Aguzzi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

Review 6.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

7.  Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation.

Authors:  Yvonne S Eisele; Tristan Bolmont; Mathias Heikenwalder; Franziska Langer; Laura H Jacobson; Zheng-Xin Yan; Klaus Roth; Adriano Aguzzi; Matthias Staufenbiel; Lary C Walker; Mathias Jucker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

8.  High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice.

Authors:  F Goñi; F Prelli; F Schreiber; H Scholtzova; E Chung; R Kascsak; D R Brown; E M Sigurdsson; J A Chabalgoity; T Wisniewski
Journal:  Neuroscience       Date:  2008-03-06       Impact factor: 3.590

9.  Chemical and biophysical insights into the propagation of prion strains.

Authors:  Jeppe Falsig; K Peterr Nilsson; Tuomas P J Knowles; Adriano Aguzzi
Journal:  HFSP J       Date:  2008-10-13

10.  Antiprion prophylaxis by gene transfer of a soluble prion antagonist.

Authors:  Nicolas Genoud; David Ott; Nathalie Braun; Marco Prinz; Petra Schwarz; Ueli Suter; Didier Trono; Adriano Aguzzi
Journal:  Am J Pathol       Date:  2008-03-27       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.